Chuang Yi Biotech co., ltd.

TPEX:6566 Stock Report

Market Cap: NT$176.5m

Chuang Yi Biotech Past Earnings Performance

Past criteria checks 0/6

Chuang Yi Biotech's earnings have been declining at an average annual rate of -2.2%, while the Pharmaceuticals industry saw earnings growing at 18.5% annually. Revenues have been declining at an average rate of 2.9% per year.

Key information

-2.2%

Earnings growth rate

-1.6%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate-2.9%
Return on equity-25.5%
Net Margin-13.6%
Last Earnings Update30 Jun 2022

Recent past performance updates

Why Chuang Yi Biotech's (GTSM:6566) Earnings Are Weaker Than They Seem

Apr 29
Why Chuang Yi Biotech's (GTSM:6566) Earnings Are Weaker Than They Seem

Recent updates

Why Chuang Yi Biotech's (GTSM:6566) Earnings Are Weaker Than They Seem

Apr 29
Why Chuang Yi Biotech's (GTSM:6566) Earnings Are Weaker Than They Seem

Is Chuang Yi Biotech (GTSM:6566) Using Too Much Debt?

Dec 23
Is Chuang Yi Biotech (GTSM:6566) Using Too Much Debt?

Revenue & Expenses Breakdown

How Chuang Yi Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:6566 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 22252-34974
31 Mar 22257-33983
31 Dec 21261-32993
30 Sep 21235151012
30 Jun 21209611031
31 Mar 2119465981
31 Dec 2017970931
30 Sep 20101-105954
30 Jun 2023-279977
31 Mar 2049-28511410
31 Dec 1975-29013113
30 Sep 19193-14413813
30 Jun 19312214612
31 Mar 19324-115513
31 Dec 18336-316313
30 Sep 18331615813
30 Jun 183251515213
31 Mar 182831013515
31 Dec 17241411817
30 Sep 17168-2411119
30 Jun 1794-5210321
31 Mar 1795-4810018
31 Dec 1696-449816
30 Sep 1698-439517
30 Jun 16101-419318
31 Mar 1698-388719
31 Dec 1594-358119

Quality Earnings: 6566 is currently unprofitable.

Growing Profit Margin: 6566 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6566 is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.

Accelerating Growth: Unable to compare 6566's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6566 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10.2%).


Return on Equity

High ROE: 6566 has a negative Return on Equity (-25.47%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/10/23 08:01
End of Day Share Price 2022/10/14 00:00
Earnings2022/06/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chuang Yi Biotech co., ltd. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution